1
|
Emuron D, Thomas K, Mullane R. The Nutritional Risk Index as a Predictor of 90-Day Dialysis Dependence After Acute Renal Failure: A Pilot Study. J Ren Nutr 2023; 33:29-34. [PMID: 35447334 DOI: 10.1053/j.jrn.2022.03.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Accepted: 03/28/2022] [Indexed: 01/25/2023] Open
Abstract
OBJECTIVE Return of sufficient renal function to discontinue dialysis following acute renal failure is an important clinical and patient-oriented outcome. Our study sought to develop a model using the Nutritional Risk Index (NRI) to predict 90-day dialysis dependence. METHODS We retrospectively analyzed 77 patients with acute renal failure admitted to a single university medical center's intensive care units between January 2015 and January 2019 with the need for continuous renal replacement therapy. We assessed the predictive ability of the NRI for 90-day dialysis dependence using age, serum total protein, number of vasopressor days, baseline predialysis estimated glomerular filtration rate (eGFR), and Sequential Organ Failure Assessment (SOFA) score as covariates. RESULTS Of the analytic group, 20 (25.9%) had severe nutritional risk, and 16 (20.8%) recovered from acute renal failure at 90 days. The mean age was 57.1 years. The clinical model comprising the NRI, age, serum total protein, number of vasopressor days, SOFA score, and baseline predialysis eGFR had an area under the curve (AUC) of 0.89 (95% confidence interval [CI], 0.81-0.97), sensitivity 56.3%, and specificity 95%. Exclusion of baseline predialysis eGFR and SOFA score did not significantly decrease model discrimination, AUC 0.87 (95% CI, 0.78-0.97). The AUC was least when serum total protein was dropped from the final model, 0.79 (95% CI, 0.66-0.92). CONCLUSIONS The NRI when used together with other clinical parameters, including serum total protein, may improve the accuracy of predicting renal recovery and independence from dialysis at 90 days.
Collapse
Affiliation(s)
- Dennis Emuron
- Fellow, Division of Nephrology, University of Nebraska Medical Center, Omaha, Nebraska
| | - Kaleb Thomas
- Resident, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
| | - Ryan Mullane
- Assistant Professor, Division of Nephrology, University of Nebraska Medical Center, Omaha, Nebraska.
| |
Collapse
|
2
|
Hettenbaugh J, Mullane R, Gillispie G, Shostrom V, Flores L, Fillaus JA, Florescu MC, Murcek D, Tendulkar KK. Hepatitis B Vaccination in Advanced Chronic Kidney Disease: A Quality Improvement Project at a Veteran Affairs Chronic Kidney Disease Clinic. Infect Dis Rep 2021; 13:1036-1042. [PMID: 34940404 PMCID: PMC8701395 DOI: 10.3390/idr13040094] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Revised: 11/29/2021] [Accepted: 11/29/2021] [Indexed: 11/19/2022] Open
Abstract
Hepatitis B vaccination is recommended in all patients with end-stage kidney disease (ESKD). However, only 50–60% of these patients achieve protective antibody levels if immunized after starting dialysis. Strategies to overcome this low seroconversion rate include a 6-month vaccination schedule starting earlier [chronic kidney disease (CKD) stage 4 and 5] to ensure immunity when patients progress to ESKD. We conducted a quality improvement program to immunize pre-dialysis patients. Patients who were found to have a negative baseline serology with a negative hepatitis B surface antibody level (HBsAb) were offered vaccination on a 6-month schedule (0, 1 and 6 months) with one of two available vaccines within the VA system (Recombivax™ or Engerix™). HBsAb titers were checked 3–4 months later, and titers ≥ 12 mIU/mL were indicative of immunity at VA. Patients who did not seroconvert were offered a repeat schedule of three more doses. We screened 198 patients (187 males and 11 females) with CKD 4 and 5 [glomerular filtration rate (GFR) < 29 mL/min/1.73 m2]. The median age of this cohort was 72 years (range 38–92 years). During the study period of 5 years (2015–2020), 10 patients were excluded since their GFR had improved to more than 30 mL/min/1.73 m2, 24 others had baseline immunity and 2 refused vaccination. The hepatitis B vaccination series was not started on 106 patients. Of the remaining 56, 12 patients progressed to ESKD and started dialysis before completion of the vaccination schedule, 6 expired and 1 did not come to clinic in 2020 due to the pandemic. Of the 37 patients who completed the vaccination schedule, 16 achieved seroconversion with adequate HBsAb titers, 10 did not develop immunity despite a second hepatitis B vaccination series, while 11 did not get a second series. Given the low seroconversion rate, albeit in a small cohort, vaccination should be considered in patients with earlier stages of CKD. Other options include studies on FDA approved vaccines of shorter duration. We plan to increase awareness among nephrologists, patients and nursing staff about the importance of achieving immunity against hepatitis B.
Collapse
Affiliation(s)
- Jacob Hettenbaugh
- Department of Internal Medicine, Division of Nephrology, University of Nebraska Medical Center, Omaha, NE 68138, USA; (J.H.); (R.M.); (G.G.); (V.S.); (L.F.); (J.A.F.); (M.C.F.); (D.M.)
- VA Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA
| | - Ryan Mullane
- Department of Internal Medicine, Division of Nephrology, University of Nebraska Medical Center, Omaha, NE 68138, USA; (J.H.); (R.M.); (G.G.); (V.S.); (L.F.); (J.A.F.); (M.C.F.); (D.M.)
- VA Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA
| | - Gayle Gillispie
- Department of Internal Medicine, Division of Nephrology, University of Nebraska Medical Center, Omaha, NE 68138, USA; (J.H.); (R.M.); (G.G.); (V.S.); (L.F.); (J.A.F.); (M.C.F.); (D.M.)
- VA Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA
| | - Valerie Shostrom
- Department of Internal Medicine, Division of Nephrology, University of Nebraska Medical Center, Omaha, NE 68138, USA; (J.H.); (R.M.); (G.G.); (V.S.); (L.F.); (J.A.F.); (M.C.F.); (D.M.)
- VA Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA
| | - Linda Flores
- Department of Internal Medicine, Division of Nephrology, University of Nebraska Medical Center, Omaha, NE 68138, USA; (J.H.); (R.M.); (G.G.); (V.S.); (L.F.); (J.A.F.); (M.C.F.); (D.M.)
- VA Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA
| | - Jennifer A. Fillaus
- Department of Internal Medicine, Division of Nephrology, University of Nebraska Medical Center, Omaha, NE 68138, USA; (J.H.); (R.M.); (G.G.); (V.S.); (L.F.); (J.A.F.); (M.C.F.); (D.M.)
- VA Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA
| | - Marius C. Florescu
- Department of Internal Medicine, Division of Nephrology, University of Nebraska Medical Center, Omaha, NE 68138, USA; (J.H.); (R.M.); (G.G.); (V.S.); (L.F.); (J.A.F.); (M.C.F.); (D.M.)
- VA Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA
| | - Denise Murcek
- Department of Internal Medicine, Division of Nephrology, University of Nebraska Medical Center, Omaha, NE 68138, USA; (J.H.); (R.M.); (G.G.); (V.S.); (L.F.); (J.A.F.); (M.C.F.); (D.M.)
- VA Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA
| | - Ketki K. Tendulkar
- Department of Internal Medicine, Division of Nephrology, University of Nebraska Medical Center, Omaha, NE 68138, USA; (J.H.); (R.M.); (G.G.); (V.S.); (L.F.); (J.A.F.); (M.C.F.); (D.M.)
- VA Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA
- Correspondence: ; Tel.: +1-402-559-9227
| |
Collapse
|
3
|
Westphal SG, Langewisch ED, Robinson AM, Wilk AR, Dong JJ, Plumb TJ, Mullane R, Merani S, Hoffman AL, Maskin A, Miles CD. The impact of multi-organ transplant allocation priority on waitlisted kidney transplant candidates. Am J Transplant 2021; 21:2161-2174. [PMID: 33140571 DOI: 10.1111/ajt.16390] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 10/26/2020] [Accepted: 10/27/2020] [Indexed: 01/25/2023]
Abstract
Kidney-alone transplant (KAT) candidates may be disadvantaged by the allocation priority given to multi-organ transplant (MOT) candidates. This study identified potential KAT candidates not receiving a given kidney offer due to its allocation for MOT. Using the Organ Procurement and Transplant Network (OPTN) database, we identified deceased donors from 2002 to 2017 who had one kidney allocated for MOT and the other kidney allocated for KAT or simultaneous pancreas-kidney transplant (SPK) (n = 7,378). Potential transplant recipient data were used to identify the "next-sequential KAT candidate" who would have received a given kidney offer had it not been allocated to a higher prioritized MOT candidate. In this analysis, next-sequential KAT candidates were younger (p < .001), more likely to be racial/ethnic minorities (p < .001), and more highly sensitized than MOT recipients (p < .001). A total of 2,113 (28.6%) next-sequential KAT candidates subsequently either died or were removed from the waiting list without receiving a transplant. In a multivariable model, despite adjacent position on the kidney match-run, mortality risk was significantly higher for next-sequential KAT candidates compared to KAT/SPK recipients (hazard ratio 1.55, 95% confidence interval 1.44, 1.66). These results highlight implications of MOT allocation prioritization, and potential consequences to KAT candidates prioritized below MOT candidates.
Collapse
Affiliation(s)
- Scott G Westphal
- Department of Internal Medicine, Nephrology Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Eric D Langewisch
- Department of Internal Medicine, Nephrology Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Amanda M Robinson
- Research Department, United Network of Organ Sharing, Richmond, Virginia, USA
| | - Amber R Wilk
- Research Department, United Network of Organ Sharing, Richmond, Virginia, USA
| | - Jianghu J Dong
- Department of Internal Medicine, Nephrology Division, University of Nebraska Medical Center, Omaha, Nebraska, USA.,Department of Biostatistics, University of Nebraska Medical Center, College of Public Health, Omaha, Nebraska, USA
| | - Troy J Plumb
- Department of Internal Medicine, Nephrology Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Ryan Mullane
- Department of Internal Medicine, Nephrology Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Shaheed Merani
- Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Arika L Hoffman
- Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Alexander Maskin
- Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Clifford D Miles
- Department of Internal Medicine, Nephrology Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| |
Collapse
|
4
|
Abstract
BACKGROUND Oftentimes, obese dialysis patients develop a viable dialysis access but the access is too deep for cannulation and needs a superficialization procedure. METHODS We present our 14-patient cohort in whom we performed liposuction to superficialize viable but deep vascular accesses. Out of 14 patients, 12 had arteriovenous fistulas and 2 arteriovenous grafts. The primary end points were the ability to superficialize a completely unusable access and to remove the hemodialysis catheter (3patients), or to significantly extend the useful length of a deep access in which only a very short segment was used and to continue to use the access post-surgery without the need to place a dialysis catheter (11 patients). RESULTS The study goal was met in 13 out of 14 patients. In two of three patients, the catheters were removed and their access usable length was 14 and 13 cm, respectively. The accesses could be used immediately after liposuction in all patients in which this applied-11 patients. The usable access length increased from a mean of 5 to 12.7 cm. The access mean depth decreased from 10.8 mm pre-surgery to 7 mm post-surgery and 5.3 mm 4 weeks after surgery. The mean volume of fat removed was 43.8 cc. We had only one surgical complication: bleeding that was readily controlled with manual pressure. All patients were discharged to home the same day. Postoperative pain was mild. CONCLUSION Liposuction is effective, safe, and seems to be the least invasive technique of superficialization.
Collapse
Affiliation(s)
- Marius C Florescu
- Nephrology Division, University of Nebraska Medical Center, Omaha, NE, USA
| | - Troy J Plumb
- Nephrology Division, University of Nebraska Medical Center, Omaha, NE, USA
| | - Scott Westphal
- Nephrology Division, University of Nebraska Medical Center, Omaha, NE, USA
| | - Ryan Mullane
- Nephrology Division, University of Nebraska Medical Center, Omaha, NE, USA
| | - Debra A Reilly
- Plastic Surgery Division, University of Nebraska Medical Center, Omaha, NE, USA
| |
Collapse
|
5
|
Mullane R, Fristoe L, Markin NW, Brakke TR, Merritt-Genore HM, Siddique A, Miles CD, Plumb TJ. Zero balance ultrafiltration using dialysate during nationwide bicarbonate shortage: a retrospective analysis. J Cardiothorac Surg 2019; 14:163. [PMID: 31500645 PMCID: PMC6734433 DOI: 10.1186/s13019-019-0986-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Accepted: 09/02/2019] [Indexed: 11/10/2022] Open
Abstract
Background Zero balance ultrafiltration (Z-BUF) utilizing injectable 8.4% sodium bicarbonate is utilized to treat hyperkalemia and metabolic acidosis associated with cardiopulmonary bypass (CPB). The nationwide shortage of injectable 8.4% sodium bicarbonate in 2017 created a predicament for the care of cardiac surgery patients. Given the uncertainty of availability of sodium bicarbonate solutions, our center pro-actively sought a solution to the sodium bicarbonate shortage by performing Z-BUF with dialysate (Z-BUF-D) replacement fluid for patients undergoing cardiopulmonary bypass. Methods Single-center, retrospective observational evaluation of the first 46 patients at an academic medical center who underwent Z-BUF using dialysate over a period of 150 days with comparison of these findings to a historical group of 39 patients who underwent Z-BUF with sodium chloride (Z-BUF-S) over the preceding 150 days. The primary outcome was the change in whole blood potassium levels pre- and post-Z-BUF-D. Secondary outcomes included changes in pre- and post-Z-BUF-D serum bicarbonate levels and the amount of serum bicarbonate used in each Z-BUF cohort (Z-BUF-D and Z-BUF-S). Results Z-BUF-D and Z-BUF-S both significantly reduced potassium levels during CPB. However, Z-BUF-D resulted in a significantly decreased need for supplemental 8.4% sodium bicarbonate administration during CPB (52 mEq ± 48 vs. 159 mEq ± 85, P < 0.01). There were no complications directly attributed to the Z-BUF procedure. Conclusion Z-BUF with dialysate appears to be analternative to Z-BUF with sodium chloride with marked lower utilization of intravenous sodium bicarbonate.
Collapse
Affiliation(s)
- Ryan Mullane
- Department of Internal Medicine, University of Nebraska Medical Center, 983040 Nebraska Medical Center, Omaha, NE, 68198-3040, USA.
| | - Lance Fristoe
- Department of Clinical Perfusion, University of Nebraska Medical Center, Omaha, NE, USA
| | - Nicholas W Markin
- Department of Anesthesiology, University of Nebraska Medical Center, Omaha, NE, USA
| | - Tara R Brakke
- Department of Anesthesiology, University of Nebraska Medical Center, Omaha, NE, USA
| | | | - Aleem Siddique
- Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA
| | - Clifford D Miles
- Department of Internal Medicine, University of Nebraska Medical Center, 983040 Nebraska Medical Center, Omaha, NE, 68198-3040, USA
| | - Troy J Plumb
- Department of Internal Medicine, University of Nebraska Medical Center, 983040 Nebraska Medical Center, Omaha, NE, 68198-3040, USA
| |
Collapse
|